Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

2026-02-20 23:03:20

Labcorp has launched the Elecsys® pTau-181 test, the first FDA-cleared blood test for Alzheimer’s disease assessment in primary care settings. This test helps clinicians rule out Alzheimer’s in symptomatic patients aged 55 and older by identifying those unlikely to have amyloid pathology. The nationwide availability expands Labcorp’s Alzheimer’s testing portfolio and provides a less invasive alternative to traditional diagnostic methods.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes